Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference

Celcuity (NASDAQ: CELC) CEO and co-founder Brian Sullivan outlined the company's clinical programs, regulatory progress, and commercial launch preparations for gedatolisib during a fireside chat at TD Cowen's 46th Annual Healthcare Conference. Sullivan described Celcuity as a clinical-stage oncology company focused on therapies that target the PI3K/AKT/mTOR (PAM) pathway, which he called "one of the most